Currently, only two TRPV1 antagonists have been reported to enter Phase III trials for atopic dermatitis (PAC-14,028) and dry eye syndrome (SYL-1001) [105] Hopefully, future clinical studies with TRPV1 receptor antagonists provide an answer as to the role of TRPV1 in inflammatory and neuropathic pain syndromes. This evidence concerns the gene TRPV1 and dry eye syndrome.